Sort
15,273 grants matching “antimicrobial resistance”
Stabilization and regulation of a Bacillus anthracis spore lytic enzyme
$223,618David L Popham · Virginia Polytechnic Inst And St Univ · R21 · FY2014 · AI
Infectious Disease Training in Clinical Investigation
$223,468University Of Minnesota Twin Cities · T32 · FY2003 · AI
Nanospray treatment of biofilm infections in wounds
$223,459Charles M. Roth · Rutgers, The State Univ Of N.J. · R21 · FY2025 · AI
Fitness Cost and Compensation in Quinolone-Resistant Mycobacterium tuberculosis
$223,400Peter M Small · Institute For Systems Biology · R21 · FY2007 · AI
Flowable antimicrobial skin scaffolding matrix that promotes regeneration
$223,369Manav Mehta · Gel4med, Inc. · R43 · FY2016 · GM
Microscopy-Based Antimicrobial Susceptibility Testing (MAST)
$223,354James E Kirby · Beth Israel Deaconess Medical Center · R21 · FY2019 · AI
Exploration of the oropharyngeal resistome as a reservoir of antimicrobial resistance in Neisseria gonorrhoeae
$223,332Olusegun Olasunkanmi Soge · University Of Washington · R21 · FY2022 · AI
Deimmunized TLR5 Agonist for Anticancer Therapy
$223,303Vadim Mett · Buffalo Biolabs, Llc · R43 · FY2014 · CA
Administrative Core
$223,288Myron Max Levine · University Of Maryland Baltimore · U19 · FY2021 · AI
Proteomic Analyses of Clostridium difficile Spore Germination Apparatus
$223,286David L Popham · Virginia Polytechnic Inst And St Univ · R21 · FY2011 · AI
Initiation and Regulation of Immune Protease Pathways
$223,283Haobo Jiang · Oklahoma State University Stillwater · R01 · FY2010 · GM
Project 3: Immunoassays for Human and Environmental Monitoring
$223,203Shirley Jacqueline Gee · University Of California At Davis · P42 · FY2013 · ES
Computational de novo design of macrocyclic type I Signal Peptidase inhibitors
$223,198Gaurav Bhardwaj · University Of Washington · R21 · FY2024 · AI
Project 2 - Toxicant-Stimulated Disruption of Gestational Tissues with Implications for Adverse Pregnancy Outcomes
$223,101Sean M Harris · Northeastern University · P42 · FY2021 · ES
COMPLEX PHENOTYPES OF MUTIPLE MUTANTS OF E COLI
$223,097University Of North Dakota · R01 · FY2001 · GM
Biorepository Core
$223,097April Bobenchik · Miriam Hospital · P20 · FY2022 · GM
Novel, Non-Toxic Ocular Antiseptic For Intravitreal Injection Therapy
$223,095Stephen J Smith · Irenix Medical, Inc. · R44 · FY2022 · EY
Infectious Disease Training in Clinical Investigation
$223,073University Of Minnesota Twin Cities · T32 · FY2004 · AI
Therapeutic Restoration of Metabolic Homeostasis During Active TB
$223,050Randall J Basaraba · Colorado State University · R21 · FY2014 · AI
LumiPhage direct ID/AST of Urinary Tract Infections
$223,024Schofield David · Guild Associates, Inc. · N43 · FY2017 · AI
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases
$222,974John McLeod Griffiss · Icon Government And Public Health Solutions, Inc. · N01 · FY2014 · AI
Novel cyclic lipopeptides for treating gram negative bacterial infections
$222,958Richard A Houghten · Torrey Pines Inst For Molecular Studies · R21 · FY2015 · AI
SnapCap: a device to decontaminate central venous catheters (CVC) with 5 snaps
$222,943Brian David Polizzotti · Contech Medical, Inc. · R41 · FY2018 · HD
PerA Helicase and Replication of Drug Resistance Plasmid
$222,938University Of Pittsburgh At Pittsburgh · R21 · FY2004 · AI
The immune serine protease pathways in Anopheles gambiae
$222,900Haobo Jiang · Oklahoma State University Stillwater · R21 · FY2025 · AI